Quantcast

Latest 5-HT3 antagonist Stories

2011-02-01 08:00:00

Patients could instantly save up to $200 off the cost of their co-pay CALIFON, NJ, Feb. 1 /PRNewswire/ - PediatRx Inc. (OTCBB: PEDX) is pleased to announce the launch of a co-pay assistance program* to support use of  GRANISOL. This unique program allows patients to instantly save up to $200 off their co-pay each time they are prescribed GRANISOL. There are various ways in which the program can be accessed. A mobile phone texting version allows patients and caregivers to text...

2011-01-06 08:00:00

CALIFON, NJ, Jan. 6 /PRNewswire/ - Hospital specialty pharmaceutical company PediatRx Inc. ("PediatRx") began trading under the symbol OTCBB:PEDX following a merger with its wholly-owned subsidiary, effective December 28, 2010. The initial PediatRx therapeutic area of focus is cancer and associated conditions/supportive care. PediatRx has acquired GRANISOL(TM), the only FDA-approved liquid oral granisetron, used for the prevention of nausea and vomiting (emesis) associated with...

2010-10-13 13:22:10

Press release from PLoS Medicine In research published this week in PLoS Medicine, Stephen Freedman (University of Toronto) and colleagues performed a cost analysis of the emergency department administration of oral ondansetron to children with dehydration and vomiting secondary to gastroenteritis and found that this treatment could provide substantial economic, as well as clinical, benefit. The researchers analyzed the costs of the administration of oral ondansetron in both the US and...

2010-08-12 00:30:00

NANJING, China, Aug. 12 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that its subsidiary company Simcere Dongyuan Pharmaceutical Co., Ltd. has recently received SFDA new drug certification and registration approval to manufacture and market Palonosetron material and...

2010-07-07 13:04:00

WARREN, N.J. and BALERNA, Switzerland, July 7 /PRNewswire/ -- MonoSol Rx, the developers of PharmFilm® technology and a drug delivery company specializing in film pharmaceutical products, in collaboration with APR Applied Pharma Research s.a. of Switzerland ("APR") and Labtec GmbH of Germany, today announced that its partner, Strativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical Companies, Inc. (NYSE: PRX), has received approval from the U.S....

2010-07-02 16:23:00

WOODCLIFF LAKE, N.J., July 2 /PRNewswire/ -- Strativa Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has approved Zuplenz® (ondansetron) oral soluble film for the prevention of postoperative, highly and moderately emetogenic cancer chemotherapy-induced, and radiotherapy-induced nausea and vomiting. Zuplenz, a unique formulation of ondansetron, is the first oral soluble film approved by the FDA as a prescription medication. The FDA...

2010-06-02 11:47:00

SCHAUMBURG, Ill., June 2 /PRNewswire/ -- Sagent Pharmaceuticals, Inc. today announced the voluntary nationwide recall of all lots of ondansetron injection in 5% dextrose 32mg / 50 mL (NDC number 25021-776-50) manufactured by Claris Lifesciences and distributed by Sagent. The lot numbers being recalled are: A090309, A090310, A090311 and A090312, which were distributed to hospitals, wholesalers and distributors nationwide from August 2009 through May 2010. Ondansetron injection is an...

2010-04-14 10:12:00

SCHAUMBURG, Ill., April 14 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has approved the Company's two abbreviated New Drug Applications (ANDAs) to market granisetron hydrochloride injection, USP (granisetron), an antiemetic used to prevent nausea and vomiting caused by chemotherapy. Granisetron will be made available in 0.1 mg per mL and 1.0 mg per mL single-dose vials, and 4.0...

2009-09-09 03:20:00

LUGANO, Switzerland, September 9 /PRNewswire/ -- As part of the Helsinn Group's development strategy, William Mann, PhD, has been appointed as new CEO in the American subsidiary, Helsinn Therapeutics (U.S.) Inc. William Mann, PhD, was already Chief Operating Officer of the recently acquired Helsinn Therapeutics, and has held leadership positions in a Swiss multinational with positions in Business Development and in Research. Moreover, Helsinn announces that Mr. William Brown has been...

2009-08-04 12:52:00

SCHAUMBURG, Ill., Aug. 4 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, today announced that it has launched ondansetron in 5% dextrose injection in premix bags, an antiemetic and selective 5-HT3 receptor antagonist used to prevent nausea and vomiting caused by chemotherapy. Sagent's ondansetron in 5% dextrose injection in premix bags is the generic equivalent of GlaxoSmithKline's ZOFRAN(R) Injection Premixed. Sagent will begin marketing...


Word of the Day
abrosia
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.